These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 27823771)

  • 21. The combination of cisplatin and topotecan as a second-line treatment for patients with advanced/recurrent uterine cervix cancer.
    Moon JY; Song IC; Ko YB; Lee HJ
    Medicine (Baltimore); 2018 Apr; 97(14):e0340. PubMed ID: 29620661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.
    Fuh KC; Secord AA; Bevis KS; Huh W; ElNaggar A; Blansit K; Previs R; Tillmanns T; Kapp DS; Chan JK
    Gynecol Oncol; 2015 Dec; 139(3):413-8. PubMed ID: 26144600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
    Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.
    O'Malley DM; Richardson DL; Rheaume PS; Salani R; Eisenhauer EL; McCann GA; Fowler JM; Copeland LJ; Cohn DE; Backes FJ
    Gynecol Oncol; 2011 May; 121(2):269-72. PubMed ID: 21315428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
    Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
    Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma.
    Rose PG; Ali S; Moslemi-Kebria M; Simpkins F
    Int J Gynecol Cancer; 2017 Mar; 27(3):452-458. PubMed ID: 28187088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma.
    Tiersten AD; Selleck MJ; Hershman DL; Smith D; Resnik EE; Troxel AB; Brafman LB; Shriberg L
    Gynecol Oncol; 2004 Feb; 92(2):635-8. PubMed ID: 14766258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
    Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
    Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
    Kim SI; Lee EJ; Lee M; Chung H; Kim JW; Park NH; Song YS; Kim HS
    Int J Gynecol Cancer; 2020 Dec; 30(12):1943-1950. PubMed ID: 33055266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paclitaxel-carboplatin plus bevacizumab therapy for advanced neuroendocrine carcinoma of the uterine cervix: A retrospective case series.
    Kotaka S; Kondo E; Kawai Y; Okamoto K; Kishigami Y; Yamawaki T; Nagao K; Toru H; Suzuki S
    J Obstet Gynaecol Res; 2023 Dec; 49(12):2868-2874. PubMed ID: 37658751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy.
    Zivanovic O; Leitao MM; Park KJ; Zhao H; Diaz JP; Konner J; Alektiar K; Chi DS; Abu-Rustum NR; Aghajanian C
    Gynecol Oncol; 2009 Mar; 112(3):590-3. PubMed ID: 19110302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer.
    Musa F; Pothuri B; Blank SV; Ling HT; Speyer JL; Curtin J; Boyd L; Li X; Goldberg JD; Muggia F; Tiersten A
    Gynecol Oncol; 2017 Feb; 144(2):279-284. PubMed ID: 27931751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study.
    Kuo DY; Blank SV; Christos PJ; Kim M; Caputo TA; Pothuri B; Hershman D; Goldman N; Ivy PS; Runowicz CD; Muggia F; Goldberg GL; Einstein MH
    Gynecol Oncol; 2010 Mar; 116(3):442-6. PubMed ID: 19931137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
    Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T;
    Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
    Pfisterer J; Shannon CM; Baumann K; Rau J; Harter P; Joly F; Sehouli J; Canzler U; Schmalfeldt B; Dean AP; Hein A; Zeimet AG; Hanker LC; Petit T; Marmé F; El-Balat A; Glasspool R; de Gregorio N; Mahner S; Meniawy TM; Park-Simon TW; Mouret-Reynier MA; Costan C; Meier W; Reinthaller A; Goh JC; L'Haridon T; Baron Hay S; Kommoss S; du Bois A; Kurtz JE;
    Lancet Oncol; 2020 May; 21(5):699-709. PubMed ID: 32305099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma.
    Matsuo K; Ross MS; Yunokawa M; Johnson MS; Machida H; Omatsu K; Klobocista MM; Im DD; Satoh S; Baba T; Ikeda Y; Bush SH; Hasegawa K; Blake EA; Takekuma M; Shida M; Nishimura M; Adachi S; Pejovic T; Takeuchi S; Yokoyama T; Ueda Y; Iwasaki K; Miyake TM; Yanai S; Nagano T; Takano T; Shahzad MMK; Ueland FR; Kelley JL; Roman LD
    Gynecol Oncol; 2017 Dec; 147(3):565-571. PubMed ID: 29056442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer.
    Husain A; Wang Y; Hanker LC; Ojeda B; Anttila M; Breda E; Vuylsteke P; Pujade-Lauraine E
    Gynecol Oncol; 2016 Sep; 142(3):465-70. PubMed ID: 27184721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world Efficacy Data on Anti-Angiogenic Drugs in Recurrent Small Cell Cervical Carcinoma: A Retrospective Study.
    Qiu H; Su N; Yan S; Li J
    Technol Cancer Res Treat; 2023; 22():15330338231160393. PubMed ID: 36883253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cervical non-squamous carcinoma: an effective combination chemotherapy of taxane, anthracycline and platinum for advanced or recurrent cases.
    Kimura T; Miyatake T; Ueda Y; Ohta Y; Enomoto T; Kimura T; Kamiura S
    Eur J Obstet Gynecol Reprod Biol; 2012 Oct; 164(2):200-4. PubMed ID: 22770633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
    Sorio R; Roemer-Becuwe C; Hilpert F; Gibbs E; García Y; Kaern J; Huizing M; Witteveen P; Zagouri F; Coeffic D; Lück HJ; González-Martín A; Kristensen G; Levaché CB; Lee CK; Gebski V; Pujade-Lauraine E;
    Gynecol Oncol; 2017 Jan; 144(1):65-71. PubMed ID: 27871723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.